PGS Sample Set (PSS): PSS000874

Phenotype Clinically significant cancer were any of: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis or distant metastasis.
Sample Ancestry African unspecified

Sample Numbers

Total number
6,271 individuals
Detailed numbers
3,031 cases (48.33%)
3,240 controls
100.0% Male samples
Number of Cohort(s) 18
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
BioVU BioVU, the Vanderbilt DNA Databank project
CeRePP French Prostate Cancer Case-Control Study
CPDR Center for Prostate Disease Research
EPICAP Epidemiology of Prostate Cancer
KARUPROSTATE French West Indies Prostate cancer Study (from Karukera, the original Caribbean name of Guadeloupe)
MIAMI-WFPCS The University of Miami – Sylvester Comprehensive Cancer Center
MOFFITT The Moffitt Group
NMHS Nashville Men's Health Study
PCaP North Carolina-Louisiana Prostate Cancer Project Consortium
PCPT Prostate Cancer Prevention Trial SWOG-PCPT
PROtEuS Prostate Cancer and Environment Study
SABOR San Antonio Center of Biomarkers of Risk for Prostate Cancer
SCCS NBHS/Southern Community Cohort
SCPCS South Carolina Prostate Cancer Study
SELECT Selenium and Vitamin E Cancer Prevention Trial
SFPCS San Francisco Prostate Cancer Study
UKGPCS UK Genetic Prostate Cancer Study
WUGS Washington University Genetics Study

Additional information

PRACTICAL consortium